- Home
- LITS vs QNCX Comparison
LITS vs QNCX Comparison
Compare LITS & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LITS
- QNCX
- Stock Information
- Founded
- LITS 2000
- QNCX 2012
- Country
- LITS United States
- QNCX United States
- Employees
- LITS N/A
- QNCX N/A
- Industry
- LITS Biotechnology: Pharmaceutical Preparations
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LITS Health Care
- QNCX Health Care
- Exchange
- LITS Nasdaq
- QNCX Nasdaq
- Market Cap
- LITS 96.2M
- QNCX 100.4M
- IPO Year
- LITS N/A
- QNCX 2019
- Fundamental
- Price
- LITS $2.05
- QNCX $1.72
- Analyst Decision
- LITS
- QNCX Strong Buy
- Analyst Count
- LITS 0
- QNCX 6
- Target Price
- LITS N/A
- QNCX $8.00
- AVG Volume (30 Days)
- LITS 916.6K
- QNCX 425.4K
- Earning Date
- LITS 11-11-2025
- QNCX 11-12-2025
- Dividend Yield
- LITS N/A
- QNCX N/A
- EPS Growth
- LITS N/A
- QNCX N/A
- EPS
- LITS N/A
- QNCX N/A
- Revenue
- LITS N/A
- QNCX N/A
- Revenue This Year
- LITS N/A
- QNCX N/A
- Revenue Next Year
- LITS N/A
- QNCX N/A
- P/E Ratio
- LITS N/A
- QNCX N/A
- Revenue Growth
- LITS N/A
- QNCX N/A
- 52 Week Low
- LITS $1.46
- QNCX $0.72
- 52 Week High
- LITS $9.00
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- LITS N/A
- QNCX 45.29
- Support Level
- LITS N/A
- QNCX $1.69
- Resistance Level
- LITS N/A
- QNCX $1.88
- Average True Range (ATR)
- LITS 0.00
- QNCX 0.12
- MACD
- LITS 0.00
- QNCX -0.03
- Stochastic Oscillator
- LITS 0.00
- QNCX 6.30
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.